The article I wrote last week for FierceBiotech on the relationship between Series A funding and innovation led to an interesting discussion with Bruce Booth, partner at Atlas Venture and biotech blogger extraordinaire.
Category Archives: License
Defining Specialty Pharma: What is it, Can it Innovate, and Does it Matter?
March 15, 2012 – 10:46 am
Licensing or Acquisition? Big Pharma Shares How They (and YOU) Decide
February 8, 2012 – 6:47 pm
When I was at the Biocom Global Life Science Partnering Conference last week, one of the more interesting debates I heard was about whether it’s better to in-license an asset or acquire the whole company.
Join the Conversation